• Molecular NameThiethylperazine
  • SynonymEthylthioperazine; Theithylperazine
  • Weight399.627
  • Drugbank_IDDB00372
  • ACS_NO1420-55-9
  • Show 2D model
  • LogP (experiment)5.4
  • LogP (predicted, AB/LogP v2.0)5.59
  • pkaN/A
  • LogD (pH=7, predicted)4.41
  • Solubility (experiment)0.0000584 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.17
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds6
  • TPSA60.32
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA piperazine phenothiazine. It is approved for treating of nausea and vomiting.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThiethylperazine is metabolized to three main metabolites in urine in rats (northiethylperazine, 2-(ethylthio)-10H-phenothiazine, thiethylperazine sulfone).
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityManifestations of acute overdosage of TORECAN (thiethylperazine) can be expected to reflect the CNS effects of the drug and include extrapyramidal symptoms (E.P.S), confusion and convulsions with reduced or absent reflexes, respiratory depression and hypotension.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A